TG003
| Code | Size | Price |
|---|
| AG-CR1-3656-M001 | 1 mg | £30.00 |
Quantity:
| AG-CR1-3656-M005 | 5 mg | £90.00 |
Quantity:
| AG-CR1-3656-M025 | 25 mg | £250.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
Short Term: +4°C. Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
(Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one
Appearance:
Solid.
CAS:
300801-52-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Keep under inert gas.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C13H15NO2S/c1-4-14-11-8-10(16-3)5-6-12(11)17-13(14)7-9(2)15/h5-8H,4H2,1-3H3/b13-7-
InChiKey:
BGVLELSCIHASRV-QPEQYQDCSA-N
Long Description:
Chemical. CAS: 300801-52-9. Formula: C13H15NO2S. MW: 249.3. Synthetic. Potent, specific, reversible and ATP-competitive cell permeable inhibitor of Cdc2-like kinase (Clk) (IC50=15nM, 20nM, 200nM and >10µM for mClk4, mClk1, mClk2 and mClk3, respectively). Cdc2-like kinase (Clk), among a number of other kinases, phosphorylates serine/arginine-rich proteins which play a role in alternative splicing of pre-mRNA. DYRK1A and DYRK1B inhibitor. Splicing modulator compound. Regulates alternative splicing and reduces the phosphorylation of SF2/ASF1. Suppresses serine/arginine-rich protein phosphorylation and affects the regulation of alternative splicing by phosphorylation of SR protein both in vitro and in vivo. Potential drug for Duchenne muscular dystrophy. The reduction of Clk2 expression in the hypothalamus by chronic pharmacological inhibition abolished the anorexigenic effect of insulin and leptin, to increase body weight, fat mass, food intake and to decrease energy expenditure in mice.
MDL:
MFCD00624584
Molecular Formula:
C13H15NO2S
Molecular Weight:
249.3
Package Type:
Plastic Vial
Precautions:
P302, P352, P304, P340, P305, P351, P338
Product Description:
Potent, specific, reversible and ATP-competitive cell permeable inhibitor of Cdc2-like kinase (Clk) (IC50=15nM, 20nM, 200nM and >10µM for mClk4, mClk1, mClk2 and mClk3, respectively). Cdc2-like kinase (Clk), among a number of other kinases, phosphorylates serine/arginine-rich proteins which play a role in alternative splicing of pre-mRNA. DYRK1A and DYRK1B inhibitor. Splicing modulator compound. Regulates alternative splicing and reduces the phosphorylation of SF2/ASF1. Suppresses serine/arginine-rich protein phosphorylation and affects the regulation of alternative splicing by phosphorylation of SR protein both in vitro and in vivo. Potential drug for Duchenne muscular dystrophy. The reduction of Clk2 expression in the hypothalamus by chronic pharmacological inhibition abolished the anorexigenic effect of insulin and leptin, to increase body weight, fat mass, food intake and to decrease energy expenditure in mice.
Purity:
>98%
Signal word:
Warning
SMILES:
CC(/C=C1SC2=CC=C(OC)C=C2N1CC)=O
Solubility Chemicals:
Soluble in DMSO (20mg/ml), ethanol (15mg/ml) or DMF (15mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Manipulation of alternative splicing by a newly developed inhibitor of Clks: M. Muraki, et al.; J. Biol. Chem. 279, 24246 (2004) | Alternative splicing: a new drug target of the post-genome era: M. Hagiwara; Biochim. Biophys. Acta 1754, 324 (2005) (Review) | Chemical treatment enhances skipping of a mutated exon in the dystrophin gene: A. Nishida, et al.; Nat. Commun. 2, 308 (2001) | Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk): B.T. Mott, et al.; Bioorg. Med. Chem. Lett. 19, 6700 (2009) | Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A: Y. Ogawa, et al.; Nat. Commun. 1, 86 (2010) | Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor: K. Ninomiya, et al.; J. Cell Biol. 195, 27 (2011) | Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II: A. Foucourt, et al.; Molecules 19, 15411 (2014) | Deciphering targeting rules of splicing modulator compounds: case of TG003: M. Sakuma, et al.; BMC Mol. Biol. 16, 16 (2015) | Cdc2-like kinase 2 in the hypothalamus is necessary to maintain energy homeostasis: P.G. Quaresma, et al.; Int. J. Obes. 41, 268 (2017)
Related Products
| Product Name | Product Code | Supplier | AZ191 | AG-CR1-3657 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SB415286 | AG-CR1-3658 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SB216763 | AG-CR1-3659 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||